GlassScriptPhysician profile
Staci Johnston
NPI 1104391044
$3,116.20
in general payments reported to CMS, 2019-2025
19 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $965 · 2024: $1,345 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103 · Education: $13.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,102.86 |
| Education | $13.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.65 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.28 | 2023-2025 | Xifaxan, Plenvu |
| Ardelyx, INC. | $294.69 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $243.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $237.23 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $197.88 | 2024-2025 | Stelara, Tremfya |
| Celgene Corporation | $183.10 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $181.48 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $122.80 | 2023 | Zeposia |
| Pfizer INC. | $106.00 | 2024-2025 | |
| Genzyme Corporation | $70.62 | 2023-2025 | |
| Qol Medical, LLC | $54.13 | 2023 | Sucraid |
| Celltrion USA INC. | $37.57 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $37.02 | 2023-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $28.53 | 2023-2024 | Linzess |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.47 | 2023 | Amjevita |
| Phathom Pharmaceuticals, INC. | $21.35 | 2023 | Voquezna |
| Aimmune Therapeutics, INC. | $18.17 | 2024 | |
| Gilead Sciences, INC. | $14.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.